Related Experiment Video
Updated: May 29, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study
Raymond J Yost1, Diane M Cappelletty,
1Department of Pharmacy, Lexington VA Medical Center, Kentucky, USA.
Study Objective:
To compare the effectiveness of extended-infusion piperacillin-tazobactam with that of similar-spectrum, nonextended-infusion [H9252]-lactam antibiotics in the treatment of gram-negative infections.
Design:
Multicenter, retrospective medical record review.
Setting:
Fourteen hospitals throughout the United States.
Patients:
A total of 359 adults treated for gram-negative infections between January 1, 2007, and February 28, 2010, with either 4-hour extended-infusion piperacillin-tazobactam (186 patients) or nonextended-infusion comparator antibiotics (173 patients), which consisted of cefepime, ceftazidime, imipenem-cilastatin, meropenem, doripenem, or piperacillin-tazobactam.
Measurements And Main Results:
Deidentified data were collected on demographics, renal function, Acute Physiology and Chronic Health Evaluation II score, chronic health conditions, source of infection and type of organism, intensive care unit (ICU) length of stay, total length of stay, type and duration of antimicrobial therapy, and in-hospital mortality. The primary outcome was mortality rate of the patients receiving extended-infusion piperacillin-tazobactam versus those receiving nonextended-infusion comparator antibiotics. Secondary outcomes were hospital length of stay, ICU length of stay, and total duration of antibiotic therapy. Baseline characteristics were similar between groups, except a significantly lower proportion of patients in the extended-infusion group were treated with a concomitant intravenous aminoglycoside (5.9% vs 16.2%, p<0.01), were infected with Pseudomonas species (22.6% vs 39.9%, p<0.01), or had positive respiratory cultures (30.7% vs 43.4%, p=0.01). Antibiotic duration, hospital length of stay, and ICU length of stay were similar between groups. In-hospital mortality was significantly decreased in the extended-infusion piperacillin-tazobactam group versus those receiving comparator antibiotics (9.7% vs 17.9%, p=0.02). Multivariate analysis confirmed that extended-infusion piperacillin-tazobactam prolonged survival by 2.77 days (p<0.01) and reduced the risk of mortality (odds ratio 0.43, p=0.05).
Conclusion:
Pharmacodynamic dosing using extended-infusion piperacillintazobactam demonstrated favorable outcomes, including mortality, when compared with nonextended-infusion, similar-spectrum [H9252]-lactams in the treatment of patients with documented gram-negative infections. Prospective, randomized trials are needed to further corroborate these findings.
Insights
Extended-infusion piperacillin-tazobactam significantly reduced mortality in gram-negative infections compared to standard dosing. This pharmacodynamic approach offers improved survival outcomes for critically ill patients.
Area of Science:
- Pharmacology and Infectious Diseases
- Antimicrobial Stewardship
Background:
- Gram-negative bacterial infections pose a significant threat, necessitating effective antimicrobial strategies.
- Optimizing antibiotic dosing, such as extended infusions, may improve therapeutic outcomes.
- Piperacillin-tazobactam is a commonly used broad-spectrum antibiotic for serious infections.
Purpose of the Study:
- To compare the effectiveness of extended-infusion piperacillin-tazobactam versus standard-infusion beta-lactam antibiotics.
- To evaluate the impact on mortality and other clinical outcomes in patients with gram-negative infections.
Main Methods:
- A multicenter, retrospective review of 359 adult patients with gram-negative infections.
- Patients received either 4-hour extended-infusion piperacillin-tazobactam or nonextended-infusion comparator antibiotics.
- Data collected included demographics, infection details, and clinical outcomes like mortality and length of stay.
Main Results:
- In-hospital mortality was significantly lower in the extended-infusion piperacillin-tazobactam group (9.7% vs. 17.9%, p=0.02).
- Extended-infusion piperacillin-tazobactam was associated with a reduced risk of mortality (OR 0.43, p=0.05).
- Hospital and ICU length of stay were similar between the groups.
Conclusions:
- Extended-infusion piperacillin-tazobactam demonstrates favorable outcomes, including reduced mortality, for gram-negative infections.
- Pharmacodynamic dosing strategies may enhance the efficacy of beta-lactam antibiotics.
- Further prospective, randomized trials are recommended to confirm these findings.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Acute Pyelonephritis II: Diagnostic Studies and Management
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Acute Pyelonephritis I: Introduction
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Drug Accumulation During Multiple Dosing: Repetitive IV Injections